Literature DB >> 11488067

Pathology of autoimmune myelofibrosis. A report of three cases and a review of the literature.

R D Bass1, V Pullarkat, D I Feinstein, A Kaul, C D Winberg, R K Brynes.   

Abstract

We identified 3 patients with autoimmune myelofibrosis (AM) lacking American Rheumatism Association criteria for systemic lupus erythematosus (SLE). They had 1 or 2 cytopenias and lacked serologic evidence for SLE. Autoimmune features included psoriatic arthritis and positive direct Coombs test (DCT) result, DCT-positive autoimmune hemolytic anemia, and synovitis with polyclonal hypergammaglobulinemia. Bone marrow biopsy specimens from each patient were evaluated by routine morphologic and immunohistochemical examination. They demonstrated marked hypercellularity (2 cases) or hypocellularity (1 case), moderate erythroid hyperplasia (all cases) with left-shifted maturation (2 cases), intrasinusoidal hematopoiesis (all cases), slightly to moderately increased megakaryocytes (2 cases), and grade 3 to 4 reticulin fibrosis (all cases). All lacked basophilia, eosinophilia, bizarre megakaryocytes, clusters of megakaryocytes, and osteosclerosis. Mild to moderate bone marrow lymphocytosis was noted in all cases. In 2 cases, increased small T cells and B cells formed nonparatrabecular, loose aggregates. AM is a clinicopathologic entity that may lack features of SLE. Loose aggregates of bone marrow T and B lymphocytes and the absence of morphologic and clinical features of myeloproliferative disease or low-grade lymphoproliferative disease are clues that distinguish AM from better known causes of bone marrow fibrosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11488067     DOI: 10.1309/6Q99-VRNL-7BTP-W1G8

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  12 in total

Review 1.  An immune dysregulation in MPN.

Authors:  Giovanni Barosi
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 2.  Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications.

Authors:  Aziz Nazha; Joseph D Khoury; Raajit K Rampal; Naval Daver
Journal:  Oncologist       Date:  2015-08-24

3.  Autoimmune Myelofibrosis in Systemic Lupus Erythematosus Report of Two Cases and Review of the Literature.

Authors:  Prasad R Koduri; Mohammad Parvez; Sashidhar Kaza; S Vanajakshi
Journal:  Indian J Hematol Blood Transfus       Date:  2015-02-15       Impact factor: 0.900

4.  Primary autoimmune myelofibrosis in a 36-year-old patient presenting with isolated extreme anemia.

Authors:  Fabio P S Santos; Sergej N Konoplev; Huifang Lu; Srdan Verstovsek
Journal:  Leuk Res       Date:  2009-09-11       Impact factor: 3.156

Review 5.  Aplastic anemia as a feature of systemic lupus erythematosus: a case report and literature review.

Authors:  Émilie Chalayer; Martine Ffrench; Pascal Cathébras
Journal:  Rheumatol Int       Date:  2014-10-30       Impact factor: 3.580

6.  Association of long-term tacrolimus (FK506) therapy with abnormal megakaryocytosis, bone marrow fibrosis, and dyserythropoiesis.

Authors:  Zhongbo Yang; Thomas Loew; Richard D Hammer
Journal:  Clin Case Rep       Date:  2015-06-13

Review 7.  Bone marrow fibrosis as a feature of systemic lupus erythematosus: a case report and literature review.

Authors:  Emilie Chalayer; Martine Ffrench; Pascal Cathébras
Journal:  Springerplus       Date:  2014-07-09

8.  Autoimmune myelofibrosis and systemic lupus erythematosus in a middle-aged male presenting only with severe anemia: a case report.

Authors:  Xerxes Pundole; Sergej Konoplev; Thein Hlaing Oo; Huifang Lu
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

9.  Myelofibrosis-related arthritis successfully treated with hydroxyurea.

Authors:  Xavier Guillot; Marius Moldovan; Claire Vidon; Daniel Wendling
Journal:  Case Rep Rheumatol       Date:  2014-04-10

10.  Primary myelofibrosis: current therapeutic options.

Authors:  Paula de Melo Campos
Journal:  Rev Bras Hematol Hemoter       Date:  2016-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.